Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7 ‐mutated colorectal cancer
Molecular Oncology · 2026
DOI: 10.1002/1878-0261.70152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Vanessa Tolotto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry, Department of Medicine, Università Degli Studi di Udine, Italy. Hauptthemen laut MEDLINE: Oxaliplatin, F-Box-WD Repeat-Containing Protein 7, Colorectal Neoplasms, Histone Deacetylases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione AIRC per la Ricerca sul Cancro, Worldwide Cancer Research.
Abstract (Originalsprache)
Epigenetic plasticity and large‐scale chromatin remodeling characterize tumor evolution and the emergence of subclones resistant to conventional therapies. Catalytically inactive class IIa HDACs (HDAC4, HDAC5, HDAC7, HDAC9) control the targeted recruitment of chromatin remodeling complexes, making them attractive therapeutic targets in oncology. In this study, we found that HDAC4 is degraded by the proteasome in cancer cells with impaired DNA repair by homologous recombination and after oxaliplatin (OXPT) treatment. Genetic screening identified FBXW7 as the E3 ligase responsible for HDAC4 degradation. FBXW7 loss‐of‐function mutations are frequently found in patients with colorectal cancer (CRC) and were found associated with the development of resistance to OXPT. Forced degradation of Class IIa HDACs using a PROTAC‐based compound restored OXPT sensitivity in FBXW7‐mutated CRC cells, patient‐derived organoids (PDOs), and mice. Mechanistically, removal of HDAC4 in FBXW7‐mutated CRC treated with OXPT recreated an epigenetic state comparable to OXPT‐sensitive cells. Furthermore, patient profiling based on the epigenetic state of the super‐enhancers controlled by HDAC4 successfully identified a priori CRC patients resistant to platinum. This study supports HDAC4 as a key mediator of oxaliplatin resistance in FBXW7‐mutated CRC and highlights the remodeling of a well‐defined super‐enhancer repertoire as part of the process of OXPT resensitization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biochemistry, Department of Medicine, Università Degli Studi di Udine, Italy.
- Dipartimento di Scienze Agroalimentari, Ambientali e Animali, Università Degli Studi di Udine, Italy.
- Division of Transplant Immunology, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Medicine, Institute for Biomedicine, Università Degli Studi di Udine, Italy.
- MTTLab, Trieste, Italy.
- Laboratory of Epigenomics, Department of Medicine, Università Degli Studi di Udine, Italy.
ORCID-Profile: Claudio Brancolini, Luigi E Xodo, Eros Di Giorgio
Förderung
- Fondazione AIRC per la Ricerca sul Cancro
- Worldwide Cancer Research
Zitieren
APA
Tolotto, V., Gualandi, N., Cortolezzis, Y., Picco, R., Colitti, M., D'Este, F., Gani, M., Hancock, W. W., Terrosu, G., Degrassi, C., Agostini, F., Brancolini, C., Xodo, L. E., & Di Giorgio, E. (2026). Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7 ‐mutated colorectal cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.70152
Vancouver
Tolotto V, Gualandi N, Cortolezzis Y, Picco R, Colitti M, D'Este F, et al. Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7 ‐mutated colorectal cancer. Molecular Oncology. 2026. doi:10.1002/1878-0261.70152
BibTeX
@article{Tolotto2026,
author = {Tolotto, Vanessa and Gualandi, Nicolò and Cortolezzis, Ylenia and Picco, Raffaella and Colitti, Monica and D'Este, Francesca and Gani, Mariachiara and Hancock, Wayne W and Terrosu, Giovanni and Degrassi, Cristina and Agostini, Francesca and Brancolini, Claudio and Xodo, Luigi E and Di Giorgio, Eros},
title = {Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7 ‐mutated colorectal cancer},
journal = {Molecular Oncology},
year = {2026},
doi = {10.1002/1878-0261.70152}
}
EUVIMED